Approach to the Acute, Generalized, Blistering Patient

Seminars in Cutaneous Medicine and Surgery

Volumn 26, Issue 3, 2007, Pages 139-146

  Carr, David R ^a   Houshmand, Elizabeth ^a   Heffernan, Michael P ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

blistering; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

BETA LACTAM ANTIBIOTIC; CAPTOPRIL; CARBAMAZEPINE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DICLOFENAC; FANSIDAR; GENTAMICIN; IMMUNOGLOBULIN; INFLIXIMAB; LAMOTRIGINE; NEVIRAPINE; PENICILLAMINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; THALIDOMIDE;

ADULT; BLISTER; BULLOUS DERMATITIS; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CASE REPORT; CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EVALUATION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; MALE; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PHYSICAL EXAMINATION; PLASMAPHERESIS; REVIEW; RISK FACTOR; SCORING SYSTEM; SKIN DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADULT; BLISTER; BURN UNITS; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; EMERGENCY MEDICAL SERVICES; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; MALE; STEVENS-JOHNSON SYNDROME;

EID: 36749066555     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2007.09.006     Document Type: Review

References (91)

1. Collier P.M., and Wojnarowska F. Drug-induced linear immunoglobulin A disease. Clin Dermatol 11 (1993) 529-533
2. Uzun S., and Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol 54 (2006) 411-415
3. Elder D.E., Elenitsas R., Johnson B., et al. Lever's histopathology of the skin. (ed 2) (2007), Lippincott Williams and Wilkins, Wolters Kluwer Health 157
4. Assier H., Bastuji-Garin S., Revuz J., et al. Erythema multiforme with mucous-membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 131 (1995) 539-543
5. Bstuji-Garin S., Rzany B., Stern R.S., et al. Clinical classification of cases of toxic epidermal necrolysis. Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129 (1993) 92-96
6. Revuz J., Roujeau J.C., Guillaume J.C., et al. Treatment of toxic epidermal necrolysis. Creteil's experience. Arch Dermatol 123 (1987) 1156-1158
7. Chave T.A., Mortimer N.J., Sladden M.J., et al. Toxic epidermal necrolysis: Current evidence, practical management and future directions. Br J Dermatol 153 (2005) 241-253
8. Wolf R., Orion E., Marcos B., et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 23 (2005) 171-181
9. Pereira F., Mudgil A., and Rosmarin D. Toxic epidermal necrolysis. J Am Acad Dermatol 56 (2007) 181-200
10. Di Pascuale M.A., Espana E.M., Liu D.T., et al. Correlation of corneal complications with eyelid cicatritial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Opthalmology 112 (2005) 904-912
11. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reations to drugs. N Engl J Med 331 (1994) 1272-1285
12. Rzany B., Mockenhaupt M., Baur S., et al. Epidemiology of erythema exsudativum multiforme majus. Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): Structures and results of a population-based registry. J Clin Epidemiol 49 (1996) 769-773
13. Letko E., Papaliodis D.N., Papaliodis G.N., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature. Ann Allergy Asthma Immunol 94 (2005) 419-435
14. Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1607
15. Litt J.Z. Litt's Drug Eruption Reference Manual. (13th ed) (2007), Taylor & Francis, AMA DataSet Limited, New York
16. Garcia-Doval I., LeCleach L., Bocquet H., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 136 (2000) 323-327
17. Rzany B., Mockenhaupt M., Stocker U., et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany. Arch Dermatol 129 (1993) 1059
18. Saiag P., Caumes E., Chosidow O., et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with human immunodeficiency virus. J Am Acad Dermatol 26 (1992) 567-574
19. Todd G. Adverse Cutaneous Drug Eruptions and HIV: a Clinician's Global Perspective. Dermatol Clin 24 (2006) 459-472
20. Fagot J.P., Mockenhaupt M., Bouwes-Bavnick J.N., et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15 (2001) 1843-1848
21. Schopf E., Stuhmer A., Rzany B., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 127 (1991) 839-842
22. Revuz J., Penso D., Roujeau J.C., et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 123 (1987) 1160-1165
23. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285
24. Guegan S., Bastuji-Garin S., Poszepczynska-Guigne E., et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 126 (2006) 272-276
25. Trent J.T., Kirsner R.S., Romanelli P., et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 140 (2004) 890-892
26. Ladhani S. Recent developments in staphylococcal scalded skin syndrome. Clin Microbiol Infect 7 (2001) 301-307
27. Lina G., Gillet Y., Vandenesch F., et al. Toxin involvement in staphylococcal scalded skin syndrome. Clin Infect Dis 25 (1997) 1369-1373
28. Mockenhaupt M., Idzko M., Grosber M., et al. Epidemiology of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol 124 (2005) 700-703
29. Ladhani S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Innumol Med Microbiol 39 (2003) 181-189
30. Cribier B., Piemont Y., and Grosshans E. Staphylococcal scalded skin syndrome in adults: A clinical review illustrated with a new case. J Am Acad Dermatol 30 (1994) 319-324
31. Stanley JR, Amagai M: Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 355;17:1800-1810.
32. Ladhani S., and Evans R.W. Staphylococcal scalded skin syndrome. Arch Dis Child 78 (1998) 85-88
33. Patel G.K., and Finlay A.Y. Staphylococcal scalded skin syndrome: Diagnosis and management. Am J Clin Dermatol 4 (2003) 165-175
34. Ladhani S., Robbie S., Garratt R.C., et al. Development and evaluation of detection systems for staphylococcal exfoliative toxin A responsible for scalded-skin syndrome. J Clin Microbiol 39 (2001) 2050-2054
35. Koch P.J., Mahoney M.G., Ishikawa H., et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 137 (1997) 1091-1102
36. Ding X., Aoki V., Mascaro Jr. J.M., et al. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 109 (1997) 592-596
37. James W.D., Berger T.G., and Elston D.M. Andrew's Diseases of the Skin: Clinical Dermatology (2006), Saunders, Elsevier Inc 459
38. Darling M.R., and Daley T. Blistering mucocutaneous diseases of the oral mucosa-A review: Part 2. Pemphigus vulgaris. J Can Dent Assoc 72 (2006) 63-66
39. Scully C., and Challacombe S.J. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med 13 (2002) 397-408
40. Pereira F.A., Mudgil A.V., and Rosmarin D.M. Toxic epidermal necrolysis. J Am Acad Dermatol 56 (2007) 181-200
41. Brenner S., Bialy-Golan A., and Ruocco V. Drug-induced pemphigus. Clin Dermatol 16 (1998) 393-397
42. Nousari H.C., and Anhalt G.J. Pemphigus and bullous pemphigoid. Lancet 354 (1999) 667-672
43. Ishii K., Amagai M., Hall R.P., et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 159 (1997) 2010-2017
44. Amagai M., Komai A., Hashimoto T., et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 140 (1999) 351-357
45. Amagai M., Tsunoda K., Zillikens D., et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 40 (1999) 167-170
46. Anhalt G.J., Kim S.C., Stanley J.R., et al. Paraneoplastic pemphigus-an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323 (1990) 1729-1735
47. Wade M.S., and Black M.M. Paraneoplastic pemphigus: A brief update. Australas J Dermatol 46 (2005) 1-10
48. Lane J.E., Woody C., Davis L.S., et al. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: Case report and review of the literature. Pediatrics 114 (2004) 513-516
49. Bialy-Golan A., et al. Paraneoplastic pemphigus: Oral involvement as the sole manifestation. Acta Derm Venerol 76 (1996) 253
50. Stevens S.R., et al. Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. Arch Dermatol 129 (1993) 866
51. Amagai M., Nishikawa T., Nousari H.C., Anhalt G.J., and Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 102 (1998) 775-782
52. Kiyokawa C. Envoplakin and periplakin and the paraneoplastic pemphigus antigens. Kurume Med J 46 (1999) 71-78
53. Freedberg I.M., Eisen A.Z., Wolff K., et al. Fitzpatrick's Dermatology in General Medicine. (6th ed) (2003), Medical Publishing Division, New York, McGraw-Hill
54. Liu Z., and Diaz L.A. Bullous pemphigoid: End of the century overview. J Dermatol 28 (2001) 647-650
55. Lee J.J., and Downham. Furosemide-induced bullous pemphigoid: Case report and review of literature. J Drugs Dermatol 5 (2006) 562-564
56. Baz K., Ikizoglu G., Kaya T.I., et al. Furosemide-induced bullous pemphigoid. J Eur Acad Dermatol Venereol 16 (2002) 81-82
57. Modeste A.B., Cordel N., Courville P., et al. Bullous pemphigoid induced by spironolactone. Ann Dermatol Venereol 129 (2002) 56-58
58. Bastuji-Garin S., Joly P., Picard-Dahan C., et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 132 (1996) 272-276
59. Stanley J.R., Tanaka T., Mueller S., et al. Isolation of a complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 82 (1988) 1864-1870
60. Diaz L.A., Ratrie H., Saunders W.S., et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera: immunolocalization of this protein to the hemidesmosome. J Clin Invest 86 (1990) 1088-1094
61. Hofmeister C.C., Quinn A., Cooke K.R., et al. Graft-versus-host disease of the skin: Life and death on the epidermal edge. Biol Blood Marrow Transplant 10 (2004) 366-372
62. Schaffer J.V. The changing face of graft-versus-host disease. Semin Cutan Med Surg 25 (2006) 190-200
63. Taylor A., Gibbs P., and Bradley J.L. Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant 4 (2004) 466-474
64. Filipovich A.H., Weisdorf P., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I: Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 11 (2005) 945-956
65. Firoz B.F., Lee S.J., Nghiem P., et al. Role of skin biopsy to confirm suspected acute graft-versus-host disease. Arch Dermatol 142 (2006) 175-182
66. Zhou Y., Barnett M.J., and Rivers J.K. Clinical significance of skin biopsies in the diagnosis and management of graft-versus-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 136 (2000) 717-721
67. Nousari H.C., Kimayi-Asadi A., Caeiro J.P., et al. Clinical, demographic and immunohistologic features of vancomycin-induced linear IgA bullous disease or the skin: Report of 2 cases and review of the literature. Medicine 78 (1999) 1-8
68. Waldman M.A., Black D.R., and Callen J.P. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Dermatol 29 (2004) 633-636
69. Schulz J.T., Sheridan R.L., Ryan C.M., et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 21 (2000) 199-204
70. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
71. Faye O., and Roujeau J.C. Treatment of epidermal necrolysis with high-dose intravenous immunoglublins (IVIg): Clinical experience to date. Drugs 65 (2005) 2085-2090
72. Mittmann N., Chan B., Knowles S., et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 7 (2006) 359-368
73. Engelhardt S.L., Schurr M.J., and Helgerson R.B. Toxic epidermal necrolysis: An analysis of referral patterns and steroid usage. J Burn Care Rehabil 18 (1997) 520-524
74. Halebian P.H., Corder V.J., Madden M.R., et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204 (1986) 503-512
75. van der Meer J.B., Schuttelaar M.L., Toth G.G., et al. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. Clin Exp Dermatol 26 (2001) 654-656
76. Kardaun S.H., and Jonkman M.F. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 87 (2007) 144-148
77. Chave T.A., Mortimer N.J., Sladden M.J., et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 153 (2005) 241-253
78. Knowles S.R., and Shear N.H. Recognition and management of severe cutaneous drug reactions. Dermatol Clin 25 (2007) 245-253
79. Arevalo J.M., Lorent J.A., Gonzalez-Herrada C., et al. Treatment of toxic epidermal necrolysis with cyclosporine A. J Trauma 48 (2000) 473-478
80. Jarrett P., Rademaker M., Havill J., et al. Toxic epidermal necrolysis treated with cyclosporine and granulocyte colony stimulating factor. Clin Exp Dermatol 22 (1997) 146-147
81. Hewitt J., and Ormerod A.D. Toxic epidermal necrolysis treated with cyclosporine. Clin Exp Dermatol 17 (1992) 264-265
82. Wolkenstein P., Latarjet J., Roujeau J.C., et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352 (1998) 1586-1589
83. Haslett P.A., Corral L.G., Albert M., et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187 (1998) 1885-1892
84. Fischer M., Fiedler E., Marsch W.C., et al. Antitumour necrosis factor-á antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146 (2002) 707-708
85. Hunger R.E., Hunziker T., Buettiker U., et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-á treatment. J Allergy Clin Immunol 116 (2005) 923-924
86. Lissia M., Figus A., and Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: Preliminary report. Br J Plast Surg 58 (2005) 504-510
87. Bamichas G., Natse T., Christidou F., et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 6 (2002) 225-228
88. Chaidemenos G.C., Chrysomallis F., Sombolos K., et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 36 (1997) 218-221
89. Yamada H., Takamori K., Taguchi H., et al. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. Ther Apher 2 (1998) 153-156
90. Egan C.A., Grant W.J., Morris S.E., et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 40 (1999) 458-461
91. Kamanabroo D., Schmitz-Landgraf W., and Czarnetzki B.M. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 121 (1985) 1548-1549